NEW YORK (GenomeWeb) – Investment bank Rodman & Renshaw has initiated coverage of Nanosphere at a Buy rating and a 12-month price target of $2 per share.

The bank believes that Nanosphere's Verigene infectious disease identification system has the potential for significant sales growth. Rodman analyst Yi Chen wrote that the Verigene system and test panels are differentiated from competing systems because it's based on gold nanoparticle technology and doesn't use PCR.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.